Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Artículo científico |
| Language: | en |
| Published: |
International journal of biological macromolecules
2026
|
| Subjects: | |
| Online Access: | https://pubmed.ncbi.nlm.nih.gov/42106034/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- PSS and its trimethyl chitosan coating multivesicular liposomes ameliorate transverse aortic constriction-induced cardiac hypertrophy. Xu, Meijie Fan, Yile Fan, Zhen Wang, Dingfu Li, Dan Zou, Haimiao Wei, Mengyan Liu, Xiaolin Xue, Yiting Wang, Shixin Li, Chunxia Animals Liposomes Chitosan Cardiomegaly Alginates Aorta Signal Transduction Myocardium Transforming Growth Factor beta Rats Pathological cardiac hypertrophy is one of the main causes of heart failure, with a highly complex pathogenesis. Currently, there is no specific therapeutic drugs available in clinical practice. Propylene glycol alginate sodium sulfate (PSS) is a heparin-like drug, which plays an important role in anticoagulation, antithrombosis and lipid-lowering. Here, PSS-loaded multivesicular liposomes coated with trimethyl chitosan were developed and their therapeutic effects on ameliorating myocardial hypertrophy were investigated. The PSS-loaded multivesicular liposomes achieved high encapsulation efficiency and sustained-release of PSS. Animal-level results showed that the new PSS formulation could delay the progression of myocardial hypertrophy. Additionally, the cell-level studies identified that PSS could inhibit myocardial cell hypertrophy and prevent fibrosis through MAPK and TGF-β/Smad signaling pathways. Our research have confirmed the potential of PSS as a candidate drug for improving myocardial hypertrophy, providing an early intervention strategy to delay the progression of cardiac hypertrophy to heart failure.